Chronic Hepatitis C and Insulin Resistance

Garvan Institute of Medical Research50 enrolled

Overview

Chronic hepatitis C (CHC) is among the commonest chronic infectious disease in Australia with \>200,000 exposed persons. Amongst non-infectious chronic conditions- Type 2 diabetes, obesity and heart disease are extremely common. This study will examine the relationship between insulin resistance, fat deposition in the liver, muscle and abdomen, and liver injury due to CHC

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hepatitis C Insulin Resistance

Eligibility

Sex: MALEMin age: 25 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Caucasian male * Age: 25-55 years * Chronic Hepatitis C (PCR positive) and fibrosis ≤ F2 (if liver biopsy done) * Genotypes 1 or 3 * Due to commence antiviral therapy * BMI \< 30 Exclusion Criteria: * Cirrhosis or F3 fibrosis on liver biopsy (if done) * \> 20 g ETOH per day * Type 2 Diabetes (need an OGTT if fasting BGL\> 5.7) * Concurrent HIV * Other cause of liver disease

Locations (2)

Garvan Institute Of Medical Research

Sydney, New South Wales, Australia

Storr Liver Unit

Sydney, New South Wales, Australia

Outcomes

Primary Outcomes

Insulin Resistance by euglycaemic hyperinsulinaemic clamp Liver fat, abdominal fat and muscle fat measures

Time frame: 2 years

Secondary Outcomes

insulin resistance post treatment of Hep C

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.